Ursprung des Netzwerks ersten Grades von Filip Vanaken
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Auroch SARL
Auroch SARL Financial ConglomeratesFinance Auroch SARL is an investment fund that provides financial services. The French company was founded in 1996 and the CEO is Filip Vanaken.
18
| Private Company | Financial Conglomerates | 18 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Filip Vanaken
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
Merit Capital NV
Merit Capital NV Investment ManagersFinance Merit Capital NV is an asset management firm headquartered in Antwerp, Belgium. The firm was founded in 2000 and is a subsidiary of Duet Group Ltd. in Great Britain. Merit Capital provides investment management and private banking services to institutions and private individuals. They also manage an umbrella fund and multi-manager strategies. | Investment Managers | Director/Board Member | |
Prins Boudewijn NV
Prins Boudewijn NV Real Estate DevelopmentFinance Prins Boudewijn NV is a Belgian company that develops and constructs both residential and non-residential buildings. The private company is based in Ghent, Belgium. The company also provides real estate services. The CEOs are Dirk Declercq, Rikkert Leeman. The company was founded in 2017. | Real Estate Development | Chief Executive Officer | |
Norgine NV
Norgine NV Pharmaceuticals: MajorHealth Technology Founded in 1906, Norgine is a specialty pharmaceutical company with an extensive pan-European presence. Throughout its long history, they have sought to develop and market high quality, innovative products for the benefit of both patients and physicians. They are committed to developing products not only to treat life-threatening conditions but, importantly, to improve the quality of life for patients with a range of acute and chronic illnesses. They have a long standing tradition of building relationships, based on the highest standards, with patients, physicians, employees, partners and other key stakeholders. In the last fifteen years, they have focused on expanding its pan-European infrastructure, and have moved to strengthen the Research & Development base of the company. In addition to developing, manufacturing and marketing its own pharmaceutical products, Norgine is an ideal partner for companies seeking assistance in the development and launch of innovative pharmaceutical products across Europe. They value its development partnerships as, together with its own in-house product development; they support its growth ambitions and will help to facilitate its continued business expansion. They have the resources to bring products to market on a pan-European or single country basis, combining sales and marketing expertise together with all development, clinical research, and product registration or manufacturing resources that its partners require. In the years ahead Norgine will continue to implement this successful strategy, building on its established infrastructure, strengthening its pan-European presence and collaborating with like-minded companies and organizations. | Pharmaceuticals: Major | Sales & Marketing |
Statistik
International
Belgien | 4 |
Sektoral
Finance | 3 |
Health Technology | 2 |
Operativ
Director/Board Member | 19 |
Investment Committee Member | 1 |
Chief Executive Officer | 1 |
Sales & Marketing | 1 |
Chairman | 1 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Filip Vanaken
- Unternehmensverbindungen